HIV protease-ligand complexesCurrent Opinion in Structural Biology 1993, 3: 868874
暂无分享,去创建一个
[1] Narmada Thanki,et al. Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling , 1992, Protein science : a publication of the Protein Society.
[2] M. Weir,et al. Penicillin derived C2-symmetric dimers as novel inhibitors of HIV-1 proteinase. , 1992, Journal of medicinal chemistry.
[3] A. Tomasselli,et al. The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. , 1993, The Journal of biological chemistry.
[4] T L Blundell,et al. The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS. , 1990, Trends in biochemical sciences.
[5] A. Berger,et al. On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.
[6] K. Murthy,et al. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations. , 1994 .
[7] M. Hatada,et al. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.
[8] J. Huff,et al. HIV protease: a novel chemotherapeutic target for AIDS. , 1991, Journal of medicinal chemistry.
[9] J. Springer,et al. Binding of a Reduced-Peptide Inhibitor and a Statine-Containing Inhibitor to the Protease from the Human Immunodeficiency Virus , 1991 .
[10] M. Katharine Holloway,et al. X-Ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2 Symmetry , 1991 .
[11] A M Hassell,et al. A symmetric inhibitor binds HIV-1 protease asymmetrically. , 1993, Biochemistry.
[12] M. Jaskólski,et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.
[13] A Wlodawer,et al. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.
[14] D. Norbeck,et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.
[15] M. Navia,et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.
[16] J M Blaney,et al. A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.
[17] C. Craik,et al. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. , 1993, The Journal of biological chemistry.
[18] R. DesJarlais,et al. Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis. , 1993, Biochemistry.
[19] John P. Overington,et al. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes , 1989, Nature.
[20] P Murray-Rust,et al. A series of penicillin-derived C2-symmetric inhibitors of HIV-1 proteinase: structural and modeling studies. , 1993, Journal of medicinal chemistry.
[21] I. Kuntz,et al. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[22] C. Debouck,et al. The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.
[23] A Wlodawer,et al. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[24] A. Wlodawer,et al. The complexities of AIDS : an assessment of the HIV protease as a therapeutic target , 1991 .
[25] L J Davis,et al. Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[26] C M Cook,et al. The three-dimensional x-ray crystal structure of HIV-1 protease complexed with a hydroxyethylene inhibitor. , 1991, Advances in experimental medicine and biology.
[27] Mark A. Murcko,et al. Use of structural information in drug design , 1992, Current Biology.
[28] A. Wlodawer,et al. Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.
[29] R. Poljak,et al. The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. , 1991, Biochimie.
[30] A M Hassell,et al. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. , 1992, Biochemistry.
[31] R. Dixon,et al. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. , 1991, The Journal of biological chemistry.
[32] P. Darke,et al. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design. , 1992, Journal of Medicinal Chemistry.
[33] D. Norbeck,et al. Chapter 15. HIV Protease Inhibitors , 1991 .
[34] J. A. Martin,et al. Recent advances in the design of HIV proteinase inhibitors. , 1992, Antiviral research.
[35] Comparison of Crystal Structures of Inhibitor Complexes of the Human Immunodeficiency Virus Protease , 1992 .
[36] J. Springer,et al. Structure and function of retroviral proteases. , 1991, Annual review of biophysics and biophysical chemistry.
[37] A Wlodawer,et al. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.